Oral calcium fosfomycinPharmacokinetic/pharmacodynamic study
- Alarcia Lacalle, A 24
- Isla, A 24
- Solinís, MA 24
- Abajo, Z 3
- Cabero Zamorano, M 3
- Canut, A 14
- Rodríguez Gascón, A 24
- 1 Microbiology Service. Araba University Hospital. Vitoria-Gasteiz, Spain.
- 2 Pharmacokinetic, Nanotechnology and Gene Therapy Group (PharmaNanoGene), Faculty of Pharmacy, University of the Basque Country UPV/EHU, Paseo de la Universidad 7, Vitoria-Gasteiz, Spain.
- 3 Bioraba Health Research Institute, Clinical Trials Unit, Vitoria-Gasteiz, Spain
- 4 Bioaraba, Microbiology, Infectious Diseases, Antimicrobials and Gene Therapy Research Group, VitoriaGasteiz, Spain
ISSN: 2660-6356
Datum der Publikation: 2021
Titel der Ausgabe: XV CONGRESO DE LA SOCIEDAD ESPAÑOLA DE FARMACIA INDUSTRIA Y GALÉNICA
Ausgabe: 2
Nummer: 2
Seiten: 76-78
Art: Artikel
Andere Publikationen in: RESCIFAR Revista Española de Ciencias Farmacéuticas
Zusammenfassung
Urinary tract infections (UTIs) are some of the most common bacterial infections, affecting 150 million people each year worldwide. Calcium fosfomycin is an antimicrobial agent with indication for the treatment of uncomplicated UTIs, being Escherichia coli the most frequently isolated microorganism. EUCAST clinical breakpoint of oral fosfomycin for E. coli in uncomplicated UTI is 8 mg/L, and the epidemiologic cutoff (ECOFF) for E. coli is 4 mg/L. Urinary drug concentrations are correlated with antibacterial activity in uncomplicated UTI infections. Indeed, high urinary antimicrobial concentrations are essential for efficacy. Therefore, the objective of this study was to analyze the urine concentrations of fosfomycin after oral administration to healthy women at different dosing levels from a pharmacokinetic/ pharmacodynamic (PK/PD) point of view.